ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.87 CNY | +0.17% |
|
+9.00% | -15.70% |
| Sales 2023 * | 2.44B 336M 28.04B | Sales 2024 * | 2.91B 402M 33.51B | Capitalization | 4.07B 561M 46.78B |
|---|---|---|---|---|---|
| Net income 2023 * | 114M 15.73M 1.31B | Net income 2024 * | 280M 38.64M 3.22B | EV / Sales 2023 * | 1.67 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 1.4 x |
| P/E ratio 2023 * |
35.8
x | P/E ratio 2024 * |
14.5
x | Employees | 1,842 |
| Yield 2023 * |
0.97% | Yield 2024 * |
2.11% | Free-Float | 62.03% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.17% | ||
| 1 week | +9.00% | ||
| Current month | -1.41% | ||
| 1 month | -3.02% | ||
| 3 months | +0.85% | ||
| 6 months | -17.97% | ||
| Current year | -15.70% |
1 week
10.77
12.04
1 month
10.6013.22
Current year
7.8614.30
1 year
7.8617.64
3 years
7.8657.26
5 years
7.8670.36
10 years
6.1370.36
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Yi Shen
CEO | Chief Executive Officer | 44 | 01/09/01 |
Jun Feng Guo
DFI | Director of Finance/CFO | 39 | 26/22/26 |
Jian Hu
CHM | Chairman | 45 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Fei Zhang
BRD | Director/Board Member | 45 | 09/23/09 |
Mei Ying Mao
BRD | Director/Board Member | 61 | 09/23/09 |
Jin Sheng Hu
BRD | Director/Board Member | 69 | 01/04/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 11.87 | +0.17% | 3,858,973 |
| 25/24/25 | 11.85 | +1.11% | 4,729,560 |
| 24/24/24 | 11.72 | +2.54% | 5,146,775 |
| 23/24/23 | 11.43 | -0.26% | 3,884,120 |
| 22/24/22 | 11.46 | +5.23% | 8,015,759 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.87
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.70% | 561M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603520 Stock
